Dual Role of Interleukin-33 in Tumors

Overview

Journal Zhong Nan Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2021 Mar 8

PMID 33678654

Authors

Qianqian Liu

Di Lu

Jiahua Hu

Junchao Liang

Huoying Chen

Affiliations

Soon will be listed here.

Abstract

Interleukin-33 (IL-33) is a new member of the IL-1 cytokine family which plays roles in the nucleus as a nuclear factor and is released by damaged or necrotic cells to act as a cytokine. It can be released via damaged or necrotic cells and functions as a cytokine. The released IL-33 activates the downstream NF-κB and MAPKs signaling pathways through the isomers of the specific receptor ST2 and the interleukin-1 receptor accessory protein (IL-1RAcP), resulting in danger signals and the activated multiple immune responses. IL-33 is abnormally expressed in various tumors and involves in tumorigenesis, development, and metastasis. Moreover, IL-33 can play both pro-tumor and anti-tumor roles in the same type of tumor.

Citing Articles

Inhibition of mPFC norepinephrine improved chronic post-thoracotomy pain in adult rats.

Zhang F, Qiu W, Qing W, Li J, Chang H, Yu R Ann Med. 2025; 57(1):2451759.

PMID: 39829262 PMC: 11749160. DOI: 10.1080/07853890.2025.2451759.

References

Maywald R, Doerner S, Pastorelli L, De Salvo C, Benton S, Dawson E . IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci U S A. 2015; 112(19):E2487-96. PMC: 4434739. DOI: 10.1073/pnas.1422445112. View

Travers J, Rochman M, Miracle C, Habel J, Brusilovsky M, Caldwell J . Chromatin regulates IL-33 release and extracellular cytokine activity. Nat Commun. 2018; 9(1):3244. PMC: 6092330. DOI: 10.1038/s41467-018-05485-x. View

Yang M, Feng Y, Yue C, Xu B, Chen L, Jiang J . Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS One. 2018; 13(3):e0193428. PMC: 5834175. DOI: 10.1371/journal.pone.0193428. View

Lim H, Choi S, Cho D, Kim T . IL-33 inhibits the differentiation and immunosuppressive activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Immunol Cell Biol. 2016; 95(1):99-107. DOI: 10.1038/icb.2016.72. View

Chikhirzhina E, Starkova T, Beljajev A, Polyanichko A, Tomilin A . Functional Diversity of Non-Histone Chromosomal Protein HmgB1. Int J Mol Sci. 2020; 21(21). PMC: 7662367. DOI: 10.3390/ijms21217948. View

Dominguez D, Ye C, Geng Z, Chen S, Fan J, Qin L . Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol. 2016; 198(3):1365-1375. PMC: 5263113. DOI: 10.4049/jimmunol.1501399. View

He Z, Chen L, Souto F, Canasto-Chibuque C, Bongers G, Deshpande M . Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc mice. Sci Rep. 2017; 7(1):5520. PMC: 5511216. DOI: 10.1038/s41598-017-05716-z. View

Mertz K, Mager L, Wasmer M, Thiesler T, Koelzer V, Ruzzante G . The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology. 2016; 5(1):e1062966. PMC: 4760343. DOI: 10.1080/2162402X.2015.1062966. View

ODonnell C, Mahmoud A, Keane J, Murphy C, White D, Carey S . An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Br J Cancer. 2015; 114(1):37-43. PMC: 4716545. DOI: 10.1038/bjc.2015.433. View

10.

Martin N, Martin M . Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol. 2016; 17(2):122-31. DOI: 10.1038/ni.3370. View

11.

Drake L, Kita H . IL-33: biological properties, functions, and roles in airway disease. Immunol Rev. 2017; 278(1):173-184. PMC: 5492954. DOI: 10.1111/imr.12552. View

12.

Hu L, Fu Y, Zhang D, Zhang J . Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev. 2013; 14(4):2563-6. DOI: 10.7314/apjcp.2013.14.4.2563. View

13.

Lucarini V, Ziccheddu G, Macchia I, La Sorsa V, Peschiaroli F, Buccione C . IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology. 2017; 6(6):e1317420. PMC: 5486175. DOI: 10.1080/2162402X.2017.1317420. View

14.

Wasmer M, Krebs P . The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Front Immunol. 2017; 7:682. PMC: 5220330. DOI: 10.3389/fimmu.2016.00682. View

15.

Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W . IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun. 2014; 453(3):486-92. DOI: 10.1016/j.bbrc.2014.09.106. View

16.

Griesenauer B, Paczesny S . The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol. 2017; 8:475. PMC: 5402045. DOI: 10.3389/fimmu.2017.00475. View

17.

Kim J, Kim W, Moon U, Kim H, Choi H, Sin J . Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth. J Immunol. 2016; 196(5):2410-23. DOI: 10.4049/jimmunol.1501730. View

18.

Kim J, Lim S, Kim G, Yun H, Ahn S, Choi H . Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene. 2014; 34(38):4928-38. DOI: 10.1038/onc.2014.418. View

19.

Hong J, Kim S, Lin P . Interleukin-33 and ST2 Signaling in Tumor Microenvironment. J Interferon Cytokine Res. 2018; 39(1):61-71. PMC: 6350413. DOI: 10.1089/jir.2018.0044. View

20.

Qi L, Zhang Q, Miao Y, Kang W, Tian Z, Xu D . Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development. Int J Cancer. 2019; 146(5):1421-1434. DOI: 10.1002/ijc.32779. View